Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Mar 29, 2022 12:49pm
58 Views
Post# 34555850

RE:RE:RE:RE:More on Reverse Splits

RE:RE:RE:RE:More on Reverse SplitsI'm sorry jfm1330, but you sound like a severely novice investor.  SPC01 is not wrong about how he views the investment world and the need for THTX leadership to engage capital markets, institutional investors, and retail investors in different ways.  He's not wrong about reverse splits either.  One of my other investments did a reverse split two years ago.  It was a brutal period for them in spite of posting incredible results that no one was investing into, but after the reverse split and consistent communication, the stock has gone from $3/share to $30/share.  It's this simple.  If the results are stunning and literally no one is aware or able to buy, it literally will not matter.  THTX needs us investors to be able to capitalize on the results.  There is an art to this science.  Finance is it's own art form and a foreign language that not everyone speaks.  Same as science.  We need both here.  I've seen it over and over again in my other investments.  THTX is failing us in this regard.  
<< Previous
Bullboard Posts
Next >>